Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport for lower-limb spasticity in stroke or TBI
NCT01249404Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2011
- Primary completion
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of abobotulinumtoxinA in Lower limb spasticity (3 arms), sponsored by Ipsen. Primary endpoint: Modified Ashworth Scale Score in the Gastrocnemius-soleus Complex at 4 weeks. Started Mar 2011; status: completed.
02
Drugs
abobotulinumtoxinA
03
Conditions
Lower limb spasticity
Beyond the preview
Go deeper on NCT01249404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01249404.